AGIO · Agios Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
Market Cap
$2.03B
Shares
59.70M
Agios Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Agios Pharmaceuticals, Inc. (AGIO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$3.52M
−$81.75M
'22 Q3
22-11-03
·
$4.31M
$36.53M
'22 Q4
23-02-23
▲574.2%
$5.61M
−$81.02M
'23 Q1
23-05-04
▲20.2%
$6.71M
−$83.81M
'23 Q2
23-08-03
▲110.4%
$7.40M
−$91.32M
'23 Q3
23-11-02
▲64.8%
$7.10M
−$95.94M
'23 Q4
24-02-15
▲46%
$8.19M
−$81.55M
'24 Q1
24-05-02
▲28.4%
$8.62M
−$96.12M
'24 Q2
24-08-01
▲21.2%
$8.96M
$947.91M
'24 Q3
24-10-31
▲51.1%
$10.73M
−$96.52M
'24 Q4
25-02-13
▲6.6%
$8.73M
−$89.29M
'25 Q1
25-05-01
▲44.6%
$12.46M
−$112.02M
'25 Q2
25-07-31
▲43.7%
$12.88M
−$103.43M
'25 Q3
25-11-19
▲86.1%
$19.97M
−$108.04M
'25 Q4
26-02-12
▲137.7%
$20.75M
−$99.11M
'26 Q1
26-04-29
LATEST
▲259.3%
$44.74M
−$100.70M
'26 Q2
26-07-30
Conference
Investor event
2026-09-09
Agios Pharmaceuticals, Inc. (AGIO) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
Confident tone
Acvesme/mitapivat commercial launch in thalassemia
Pipeline expansion through business development
Financial position and capital allocation
Revenue
$44.74M
▲ 259.3% YoY Diluted EPS
$-1.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Confident tone
Sickle cell disease label expansion / sNDA
Tepofitinib / next-generation PK activator
Regulatory engagement with FDA
Revenue
$20.75M
▲ 137.7% YoY Diluted EPS
$-1.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Confident tone
ACVESME/Agvesme Launch in Thalassemia
Sickle Cell Disease Opportunity (mitapivat)
Lower-Risk MDS Pipeline (AG-236)
Revenue
$19.97M*
▲ 86.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-19
Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript
Confident tone
PYRUKYND thalassemia U.S. launch
Pipeline (Tebapivat, AG-181, AG-236)
Global commercialization partnerships
Revenue
$12.88M
▲ 43.7% YoY Diluted EPS
$-1.78
▼ 111% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
Confident tone
Thalassemia PDUFA and indication expansion
Capital-efficient ex-U.S. partnerships
Financial position and capital allocation
Revenue
$12.46M
▲ 44.6% YoY Diluted EPS
$-1.93
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
Confident tone
PYRUKYND Franchise and Commercial Expansion
Thalassemia Regulatory Review and PDUFA
Tebapivat Pipeline in MDS and Sickle Cell
Revenue
$8.73M
▲ 6.6% YoY Diluted EPS
$-1.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Confident tone
PYRUKYND franchise and commercial launches
Thalassemia regulatory progress
Pediatric PK deficiency (ACTIVATE-KIDS)
Revenue
$10.73M*
▲ 51.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
Confident tone
Mitapivat in thalassemia (sNDA submission and launch)
Sickle cell disease (RISE UP Phase 3)
PK deficiency (PYRUKYND commercial launch)
Revenue
$8.96M
▲ 21.2% YoY Diluted EPS
$16.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript
Confident tone
Mitapivat in thalassemia (ENERGIZE/ENERGIZE-T)
Sickle cell disease (RISE UP)
Pediatric PK deficiency (ACTIVATE-kids T)
Revenue
$8.62M
▲ 28.4% YoY Diluted EPS
$-1.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript
Confident tone
Mitapivat in thalassemia (ENERGIZE/ENERGIZE-T)
Ex-U.S. partnership strategy
Pipeline and clinical milestones
Revenue
$8.19M
▲ 46% YoY Diluted EPS
$-1.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Agios Pharmaceuticals, Inc. (AGIO) Q4 2023 Earnings Call Transcript
Confident tone
Mitapivat pipeline progress
Thalassemia opportunity
PK deficiency commercial launch
Revenue
$7.10M*
▲ 64.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Agios Pharmaceuticals, Inc. (AGIO) Q3 2023 Earnings Call Transcript
Revenue
$7.40M
▲ 110.4% YoY Diluted EPS
$-1.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript
Revenue
$6.71M
▲ 20.2% YoY Diluted EPS
$-1.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Agios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call Transcript
Revenue
$5.61M
▲ 574.2% YoY Diluted EPS
$-1.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript
Revenue
$4.31M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript
Revenue
$3.52M
Diluted EPS
$-1.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Agios Pharmaceuticals, Inc. (AGIO) Q2 2022 Earnings Call Transcript
Revenue
$5.58M
Diluted EPS
$-1.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Agios Pharmaceuticals, Inc. (AGIO) Q1 2022 Earnings Call Transcript
Revenue
$832,000
Diluted EPS
$-1.74
▼ 106.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Agios Pharmaceuticals, Inc. (AGIO) Q4 2021 Earnings Call Transcript
Revenue
$*
▼ 100% YoY Diluted EPS
$-1.74
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Agios Pharmaceuticals, Inc. (AGIO) Q3 2021 Earnings Call Transcript
Revenue
$
▼ 100% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Agios Pharmaceuticals, Inc. (AGIO) Q2 2021 Earnings Call Transcript
Revenue
$
▼ 100% YoY Diluted EPS
$-1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Agios Pharmaceuticals, Inc. (AGIO) Q1 2021 Earnings Call Transcript
Revenue
$
▼ 100% YoY Diluted EPS
$26.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Agios Pharmaceuticals, Inc. (AGIO) Q4 2020 Earnings Call Transcript
Revenue
$44.05M
▲ 24.3% YoY Diluted EPS
$-1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Agios Pharmaceuticals, Inc. (AGIO) Q3 2020 Earnings Call Transcript
Revenue
$34.71M
▲ 33.4% YoY Diluted EPS
$-1.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Agios Pharmaceuticals, Inc. (AGIO) Q2 2020 Earnings Call Transcript
Revenue
$37.35M
▲ 42.4% YoY Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Agios Pharmaceuticals, Inc. (AGIO) Q1 2020 Earnings Call Transcript
Revenue
$87.10M
▲ 188.1% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Agios Pharmaceuticals, Inc. (AGIO) Q4 2019 Earnings Call
Revenue
$35.44M
▲ 18.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1439222
CUSIP
00847X104
13F (30d)
12 filings
11 filers
Visit website
Investor relations